抗血栓形成药物的研究进展

doi:10.16352/j.issn.1001-6325.2023.01.0183

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (1): 183-187.doi: 10.16352/j.issn.1001-6325.2023.01.0183

抗血栓形成药物的研究进展

张杰^1,2, 麻旭州^1,2, 李慧慧^1,2, 王淼^1,2*

1.浙江师范大学化学与生命科学学院,浙江金华 321000;
2.中国医学科学院北京协和医学院国家心血管病中心阜外医院心血管疾病国家重点实验室, 北京 100037

收稿日期:2021-09-13 修回日期:2022-02-08 发布日期:2022-12-27
通讯作者: ^*wangmiao_frank@aliyun.com
基金资助:
国家重点研发计划(2020YFC2008000);中国医学科学院医学与健康技术创新工程(2017-I2M-1-008,2016-I2M-1-003)

Research progress of antithrombotic drugs

ZHANG Jie^1,2, MA Xuzhou^1,2, LI Huihui^1,2, WANG Miao^1,2*

1. College of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua 321000;
2. State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, CAMS & PUMC, Beijing 100037, China

Received:2021-09-13 Revised:2022-02-08 Published:2022-12-27
Contact: ^*wangmiao_frank@aliyun.com

摘要/Abstract

摘要： 血栓形成是动脉粥样硬化性心血管疾病患者急性表征(心肌梗死,卒中)的主要直接诱因。在全球范围内,血栓栓塞性疾病的发病率近年来有所增加,患者病死率也随之增加。目前,针对血栓栓塞性疾病,已经发展了几种靶向给药策略,其中包括抗血小板药物和抗凝血药物,随着抗血栓形成药物的研究进展,治疗血栓导致的心血管疾病为患者带来了巨大的潜在效益。

关键词: 血栓, 药物, 抗血小板, 抗凝血

Abstract: Thrombosis is the main direct cause of acute manifestations of atherosclerotic cardiovascular disease (myocardial infarction, stroke). Globally, the incidence of thromboembolic diseases has increased in recent years, accompanied by an increase in patient mortality. Currently,several targeted drug delivery strategies have been developed for thromboembolic diseases, including antiplatelet drugs and anticoagulant drugs. With the development of antithrombotic drugs, the treatment of cardiovascular diseases caused by thrombus shows significant potential benefit for patients.

Key words: thrombus, drugs, antiplatelet, anticoagulant

中图分类号:

R364.1+5

张杰, 麻旭州, 李慧慧, 王淼. 抗血栓形成药物的研究进展[J]. 基础医学与临床, 2023, 43(1): 183-187.

ZHANG Jie, MA Xuzhou, LI Huihui, WANG Miao. Research progress of antithrombotic drugs[J]. Basic & Clinical Medicine, 2023, 43(1): 183-187.

参考文献

[1] Mackman N, Bergmeier W, Stouffer GA,et al. Thera-peutic strategies for thrombosis: new targets and appro-aches[J]. Nat Rev Drug Discov, 2020,19: 333-352.
[2] 《中国心血管疾病与报告2020》编写组.《中国心血管疾病与健康》要点解读[J]. 中国心血管杂志, 2021, 26: 209-218.
[3] Roth GA,Mensah GA,Johnson CO.et al.Global burden of cardiovascular diseases and risk factors, 1990—2019: update from the GBD 2019 Study[J].J Am Coll Cardiol, 2020, 76: 2982-3021.
[4] Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture[J]. J Intern Med, 2014, 276: 618-632.
[5] Thompson AE. Deep vein thrombosis[J]. JAMA, 2015, 313: 2090-2090.
[6] Baqi Y,Muller CE.Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery[J]. Drug Discov Today,2019, 24:325-333
[7] Zwart B, Parker WAE, Storey RF. New antithrombotic drugs in acute coronary syndrome[J]. J Clin Med, 2020, 9: 2059-2077.
[8] Capodanno D, Angiolillo DJ.Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes mellitus[J]. Circulation,2020, 142:2172-2188.
[9] Patrono CM, Baigent C, Collet J,et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis[J]. JAmCollCardiol, 2017, 70: 1760-1776.
[10] Barra ME, Fanikos J, Connors JM, et al. Evaluation of dose-reduced direct oral anticoagulant therapy[J]. Am J Med, 2016, 129: 1198-1204.
[11] Warkentin TE, Pai M, and Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review[J]. Blood, 2017, 130: 1104-1113.
[12] Schüpke S,Hein-Rothweiler S,Mayer K, et al. Revacept, a novel inhibitor of platelet adhesion, in patients undergoing elective pci-design and rationale of the randomized isar-plaster trial[J]. Thromb Haemost, 2019, 119: 1539-1545.
[13] Mayer K, Hein-Rothweiler R, Schüpke S, et al. Efficacy and safety of revacept, a novel lesion-directed competitive antagonist to platelet glycoprotein vi, in patients undergo-ing elective percutaneous coronary intervention for stable ischemic heart disease: the randomized, double-blind, placebo-controlled isar-plaster phase 2 trial[J]. JAMA Cardiol, 2021, 6: 753-761.
[14] Mackman N, Bergmeier W, Stouffer GA, et al.Therapeu-tic strategies for thrombosis: new targets and approaches[J]. Nat Rev Drug Discov 2020, 19: 333-352.
[15] Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events[J]. N Engl J Med, 2012, 366: 1404-1413.
[16] Suehiro E, Fujiyama Y, Kiyohira M, et al. Risk of deterioration of geriatric traumatic brain injury in patients treated with antithrombotic drugs[J].World Neurosurg,2019, 127:e1221-e1227.
[17] Weitz JI,Chan NC. Novel antithrombotic strategies for treatment of venous thromboembolism[J]. Blood, 2020, 135: 351-359.
[18] Lorentz CU, Verbout NG, Wallisch M,et al.Contact activation inhibitor and factor Ⅺ antibody, ab023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial[J]. Arterioscler Thromb Vasc Biol, 2019, 39: 799-809.
[19] Koch AW, Schiering N, Melkko S, et al.MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans[J]. Blood, 2019, 133: 1507-1516.
[20] Pireaux V, Tassignon J, Demoulin S, et al. Anticoagula-tion with an inhibitor of factors Ⅺa and Ⅻa during cardiopulmonary bypass[J]. J Am Coll Cardiol, 2019, 74: 2178-2189.
[21] Bauml M, Hilgendorf I. Future antithrombotic therapies in cardiology[J]. Hamostaseologie, 2018, 38: 236-239.
[22] Bielecki S, Lee D,Hamad B. The market for oral anticoagulants[J]. Nat Rev Drug Discov, 2018, 17: 617-618.

抗血栓形成药物的研究进展

Research progress of antithrombotic drugs

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王靓, 夏隆阔, 张建民. 脑类器官在药物研发中的研究进展[J]. 基础医学与临床, 2024, 44(9): 1208-1213.
[2]	胡崧, 华潞, 张健. 肺动脉高压的抗凝治疗:必要性与困境[J]. 基础医学与临床, 2024, 44(8): 1062-1067.
[3]	高艺丹, 蒋雪涵, 张红, 杨沛然. 靶向异常通路的动脉性肺动脉高压新型药物研发[J]. 基础医学与临床, 2024, 44(8): 1088-1093.
[4]	谢芳菲, 李双玲, 王春梅. ICU危重患者静脉血栓栓塞症预防策略[J]. 基础医学与临床, 2024, 44(7): 906-911.
[5]	李佩娟, 王春梅, 赵茜. 三七总皂苷预防血栓的机制[J]. 基础医学与临床, 2024, 44(7): 912-915.
[6]	丁梦希, 王春梅. 老年患者静脉血栓栓塞症的预防[J]. 基础医学与临床, 2024, 44(7): 916-920.
[7]	张妍祺, 闫彬, 宁雅婵, 余雪渊, 王春梅. 静脉外膜囊性疾病的诊断与治疗[J]. 基础医学与临床, 2024, 44(7): 921-924.
[8]	邹文兵, 王安仙, 曹政媛. 贵阳地区原发性高血压患者降压药物疗效相关基因的多态性[J]. 基础医学与临床, 2024, 44(7): 979-983.
[9]	张沥元, 杜函泽, 潘慧. 治疗下丘脑性肥胖的药物研究进展[J]. 基础医学与临床, 2024, 44(5): 729-732.
[10]	胡子衿, 孔燕, 吴晓雯, 郭倩, 郭军. Sitravatinib联合Niraparib对黏膜黑色素瘤细胞系增殖、凋亡和自噬的影响及其机制[J]. 基础医学与临床, 2024, 44(3): 295-302.
[11]	鞠瑞, 王钰铖, 朱蕾, 于晓丽, 董燕, 郭磊. 用药过程三幕微情境课堂教学设计及其在护理药物学教学中的应用[J]. 基础医学与临床, 2023, 43(12): 1905-1910.
[12]	王钰铖, 鞠瑞, 郭磊. 微课联合CBL在护理本科药物治疗学教学中的应用及评价[J]. 基础医学与临床, 2023, 43(11): 1743-1749.
[13]	沙务嘎, 李隽. 高通量筛选NMNAT1抑制剂及其肿瘤杀伤作用[J]. 基础医学与临床, 2022, 42(6): 933-939.
[14]	左宇志, 严维刚. 抗血栓药物的应用与前列腺穿刺活检术的安全性[J]. 基础医学与临床, 2022, 42(5): 824-827.
[15]	赵川榕, 周菁. 靶向剪切力敏感关键分子的动脉粥样硬化防治研究[J]. 基础医学与临床, 2022, 42(3): 378-383.